When pressed for 2025 expectations, Verona believed $254 million in revenues was a fair estimate. Critically, Verona expects ...

Anticipating a rising need for individually wrapped vial medication manufacturing, The Ritedose Corporation, Inc. (Ritedose) ...

Ritedose, a sterile contract manufacturing organisation, is expanding its manufacturing facility with a seventh ...

Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for ...

If you need financial support to pay for Ohtuvayre, or if you need help understanding your insurance coverage, help is available. For example: A program called Verona Pathway Plus is available for ...

“2024 was another transformational year for Verona with the approval and US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (“COPD ...

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs.

If you need financial support to pay for Ohtuvayre or help understanding your insurance coverage, assistance is available. For example: A program called Verona Pathway Plus is available for Ohtuvayre.

and now Verona has revealed the drug made approximately $36 million in the final three months of 2024, off more than 16,000 prescriptions. Chief executive David Zaccardelli said Ohtuvayre was off ...

(RTTNews) - Verona Pharma plc (VRNA), Friday announced some strategic changes in its capital structure, increasing the company's financial flexibility and simplifying its balance sheet. The ...